Use of 5-Alpha-Reductase Inhibitors Did Not Increase the Risk of Cardiovascular Diseases in Patients with Benign Prostate Hyperplasia: A Five-Year Follow-Up Study

Eitemau Tebyg

• Use of 5-alpha-reductase inhibitors did not increase the risk of cardiovascular diseases in patients with benign prostate hyperplasia: a five-year follow-up study.
  gan: Teng-Fu Hsieh, et al.
  Cyhoeddwyd: (2015-01-01)
• The use of 5-alpha reductase inhibitors in the treatment of benign prostatic hyperplasia
  gan: Kim, Eric H., et al.
  Cyhoeddwyd: (2018)
• CHADS2 scores as a predictor of ischemic stroke after radical prostatectomy
  gan: Yang, Yu‐Wan, et al.
  Cyhoeddwyd: (2015)
• Maximum Urine Flow Rate of Less than 15ml/Sec Increasing Risk of Urine Retention and Prostate Surgery among Patients with Alpha-1 Blockers: A 10-Year Follow Up Study
  gan: Liu, Hsin-Ho, et al.
  Cyhoeddwyd: (2016)
• A Population-Based Nested Case-Control Study in Taiwan: Use of 5α-Reductase Inhibitors Did Not Decrease Prostate Cancer Risk in Patients with Benign Prostate Hyperplasia
  gan: Liang, Ji-An, et al.
  Cyhoeddwyd: (2012)